2021
-
Heather A. Wakelee, MD
Heather A. Wakelee, MD, has been promoted to Chief of the Division of Oncology at Stanford University. She has also assumed the role of Deputy Director of the Stanford Cancer […]
-
The New WHO Classification of Lung Tumors
Ming S. Tsao, MD, FRCPC, of the Princess Margaret Cancer Centre, Toronto, delivered a Plenary Presentation during the 2020 World Conference on Lung Cancer outlining key updates found in the […]
-
Patient Advocate Comment: Amivantamab for Exon 20
Amivantamab for Exon 20-Related NSCLC: Excitement in the Patient Community We look forward to Dr. Joshua Sabari’s presentation during the oral abstract presentation session “OA04: new Data from Rare EGFR […]
-
Comparing Patient-Reported Outcomes in the CROWN Study
The abstract “Patient-reported outcomes from the randomized Phase 3 CROWN study of first-line lorlatinib versus crizotinib in ALK+ NSCLC” by Mazieres et al., presents a welcome analysis of symptoms and […]
-
Cultural Perceptions of End-of-Life Communication
Palliative and end of life care discussions are significant and essential, yet sensitive and challenging. Cultural perceptions of pain and end of life can filter nuances in provider communication in […]
-
Hereditary Predisposition Plays a Larger Role in SCLC Development Than Previously Recognized and May Inform Personalized Treatment
Whole-exome sequencing reveals that almost half of all patients with small cell lung cancer (SCLC) have a deleterious germline mutation which may be associated with the development of their disease […]
-
Presidential Symposium Findings
Read the full articles for detailed summaries of each presentation. TALENT: This national lung cancer screening study conducted in Taiwan in 12,011 individuals, uncovered the presence of lung cancer in […]
-
ADAURA: Data is Only Part of the Story
Patient Research Advocate (PRA) and 12-year survivor, Jill Feldman, discusses scientific and humanistic concerns regarding the ADAURA trials current data on disease-free progression in NSCLC. As a patient, osimertinib has […]
-
Patient Comment on Mobocertinib for Exon 20
Mobocertinib for Exon 20-Related Lung Cancer of Great Interest to Patients My brother Kevin, who founded the Exon 20 Group at ICAN with me in early 2017, started on mobocertinib […]
-
Improved Screening Uptake Could Help Double Lung Cancer Survival by 2025
Between 60% and 65% of patients with lung cancer receive their diagnoses at stage III or IV, meaning that one-third are unaware of their disease when radical surgery, either alone […]
View ILCN Archives
Provider Resources